Related Experiment Video
Updated: Jul 20, 2026
05:35
A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
Published on: January 19, 2024
Iron supplementation in renal anemia.
1Winthrop-University Hospital, Mineola, NY, USA. sfishbane@metrorenal.com
Seminars in Nephrology
|September 5, 2006
Summary
Iron deficiency is common in chronic kidney disease patients on recombinant human erythropoietin (rHuEPO) therapy, hindering anemia treatment. Effective iron management is crucial for achieving hemoglobin targets in these patients.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Anemia is a common complication in chronic kidney disease (CKD).
- Recombinant human erythropoietin (rHuEPO) therapy is standard for CKD anemia.
- Iron deficiency frequently complicates rHuEPO therapy, reducing its effectiveness.
Purpose of the Study:
- To review the physiology of iron balance.
- To discuss iron balance derangements in CKD patients.
- To outline the diagnosis and treatment of iron deficiency in CKD patients receiving rHuEPO.
Main Methods:
- Literature review of iron metabolism and anemia management in CKD.
- Discussion of clinical guidelines and evidence-based practices.
- Synthesis of information on iron physiology, CKD-related derangements, and treatment strategies.
Main Results:
- Iron deficiency impairs rHuEPO efficacy, leading to suboptimal hemoglobin levels.
- Accurate monitoring and timely iron supplementation are essential for successful anemia management.
- Understanding iron balance is key to optimizing rHuEPO therapy outcomes.
Conclusions:
- Iron management is a cornerstone of anemia therapy in CKD patients treated with rHuEPO.
- Addressing iron deficiency is critical for achieving therapeutic goals and improving patient outcomes.
- This review provides a comprehensive overview for clinicians managing iron status in CKD.
Related Concept Videos
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:22Acute Kidney Injury I: Introduction
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...